Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
China Shineway Pharmaceutical Group Limited (CSWYF)
Shijiazhuang, CN
China Shineway Pharmaceutical Group Limited functions as an investment holding company, primarily engaged in the development, manufacturing, and commercialization of traditional Chinese medicines. Its operations span across the People's Republic of China and Hong Kong. The company's diverse product portfolio includes contemporary Chinese medicines, supplied in formats such as soft capsules, granules, and injections, alongside traditional Chinese medicine (TCM) Formula Granules. These offerings target a wide array of therapeutic fields, including cardiovascular and cerebrovascular health, anti-viral applications, orthopedic care, pediatric medicine, women's health, and digestive system disorders. Beyond pharmaceuticals, the company also participates in the trading of agricultural goods. Established in 2004, China Shineway Pharmaceutical Group Limited has its headquarters situated in Shijiazhuang, PRC, and operates as a subsidiary of Forway Investment Limited.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.40% | +0.40% | +0.40% | +0.40% | +0.40% | +0.40% | +6.72% | -19.03% | -19.03% | -4.38% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-17.0% Q4'24: +1,038.1% (vs Q4'22)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+13.5% Q4'24: +1,236.6% (vs Q4'22)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+46.3% ★ Q4'24: +21.6% (vs Q4'22)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+40.7% ★ Q4'24: +30.8% (vs Q4'22)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+114.8% ★ Q4'24: +379.7% (vs Q4'22)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.0% Q4'24: +0.0% (vs Q4'22)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.25× ★ Q4'24: 0.07× (vs Q4'22)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
327.03M
est: 339.78M (-3.7%)
|
300.41M
est: 265.77M (+13.0%)
|
283.15M
est: 283.86M (-0.2%)
|
388.83M
est: 373.11M (+4.2%)
|
393.80M
est: 402.45M (-2.2%)
|
384.87M
est: 410.52M (-6.3%)
|
498.18M
est: 513.74M (-3.0%)
|
588.09M
est: 557.11M (+5.6%)
|
4.52B
est: 4.65B (-2.8%)
|
3.78B
est: 4.41B (-14.4%)
|
3.14B
est: 3.13B (+0.1%)
|
3.03B
3.03B – 3.03B
-3.2% YoY
|
3.26B
3.26B – 3.26B
+7.6% YoY
|
| EBITDA |
123.61M
est: 66.66M (+85.4%)
|
111.40M
est: 52.14M (+113.6%)
|
66.96M
est: 55.69M (+20.2%)
|
107.41M
est: 73.20M (+46.7%)
|
76.52M
est: 78.96M (-3.1%)
|
66.78M
est: 80.54M (-17.1%)
|
121.32M
est: 100.80M (+20.4%)
|
145.34M
est: 93.94M (+54.7%)
|
1.25B
est: 783.41M (+59.8%)
|
1.22B
est: 1.34B (-9.0%)
|
1.35B
est: 952.56M (+41.3%)
|
921.88M
921.88M – 921.88M
-3.2% YoY
|
991.54M
991.54M – 991.54M
+7.6% YoY
|
| EBIT |
797.23M
est: 60.81M (+1,211.1%)
|
104.78M
est: 47.56M (+120.3%)
|
86.71M
est: 50.80M (+70.7%)
|
101.23M
est: 66.77M (+51.6%)
|
645.43M
est: 72.02M (+796.1%)
|
59.65M
est: 73.47M (-18.8%)
|
111.48M
est: 91.94M (+21.3%)
|
136.60M
est: 81.46M (+67.7%)
|
1.24B
est: 679.31M (+83.0%)
|
1.15B
est: 1.27B (-9.5%)
|
1.27B
est: 904.13M (+41.0%)
|
875.01M
875.01M – 875.01M
-3.2% YoY
|
941.12M
941.12M – 941.12M
+7.6% YoY
|
| Net Income |
104.71M
est: 90.74M (+15.4%)
|
88.79M
est: 66.23M (+34.1%)
|
66.61M
est: 56.26M (+18.4%)
|
76.53M
est: 71.52M (+7.0%)
|
73.22M
est: 78.08M (-6.2%)
|
42.76M
est: 60.06M (-28.8%)
|
86.03M
est: 111.75M (-23.0%)
|
107.59M
est: 96.60M (+11.4%)
|
137.16M
est: 772.58M (-82.2%)
|
840.05M
est: 921.26M (-8.8%)
|
949.95M
est: 815.68M (+16.5%)
|
820.88M
820.88M – 820.88M
+0.6% YoY
|
921.07M
921.07M – 921.07M
+12.2% YoY
|
| SGA |
107.88M
est: 181.05M (-40.4%)
|
97.66M
est: 141.62M (-31.0%)
|
112.39M
est: 151.26M (-25.7%)
|
189.40M
est: 198.82M (-4.7%)
|
201.41M
est: 214.45M (-6.1%)
|
1.46B
est: 218.75M (+566.9%)
|
1.76B
est: 273.75M (+541.5%)
|
2.10B
est: 296.72M (+607.2%)
|
2.31B
est: 2.47B (-6.7%)
|
1.89B
est: 7.56B (-75.0%)
|
1.45B
est: 5.37B (-73.1%)
|
5.19B
5.19B – 5.19B
-3.2% YoY
|
5.59B
5.59B – 5.59B
+7.6% YoY
|
| EPS |
0.13
est: 0.12 (+8.2%)
|
0.11
est: 0.09 (+25.5%)
|
0.08
est: 0.07 (+8.1%)
|
0.09
est: 0.09 (-1.0%)
|
0.09
est: 0.10 (-9.2%)
|
0.06
est: 0.08 (-28.9%)
|
0.11
est: 0.15 (-25.6%)
|
0.14
est: 0.13 (+9.5%)
|
0.18
est: 1.02 (-82.4%)
|
1.11
est: 1.22 (-9.0%)
|
1.26
est: 1.08 (+16.7%)
|
1.09
1.09 – 1.09
+0.6% YoY
|
1.22
1.22 – 1.22
+12.2% YoY
|
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Zhenjiang Li | Co-Founder & Executive Chairman | 1M | male |
| Yunxia Xin | Co-Founder & Executive Director | 467.3K | female |
| Huimin Li | Executive Director | 309.3K | male |
| King Kuen Hung | Director of Investor Relation | 4.9K | male |
| Bun Ching Lee | Financial Controller & Company Secretary | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CSWYF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
